Research uncovers how inhibiting interactions between cyclin A and cyclin B and their key binding partners, E2F and MYT1, selectively kills E2F-high tumor cells Circle Pharma’s oral first-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback